Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2024 earnings conference call. (Operator Instructions) After the speaker's presentation, there will ...
Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...
Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback